

1 DETECTION OF AUTOLOGOUS BLOOD DOPING

2 Christer Malm,^{1,2} Irene Granlund,² Michael Hall,² Pernilla Lindén,² Magnus Ericsson,^{3,4} James I.
3 Langridge,⁵ Lee A. Gethings,⁵ Chris Hughes,⁵ and Nelson Khoo²

4 ¹Section of Sports Medicine, Department of Community Medicine and Rehabilitation, Umeå
5 University, Umeå, Sweden. ²Pro Test Diagnostics AB, Umeå, Sweden. ⁴AFLD - Agence Française de
6 Lutte contre le Dopage, Département des analyses, Châtenay-Malabry, France. ⁵Department of
7 Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. ⁵Waters Corporation, Stamford
8 Avenue, Altrincham Road, Wilmslow, UK.

9 ABSTRACT

10 **Objectives:** Autologous blood transfusion (ABT) enhances athlete's performance, is banned as doping
11 by the World Anti-Doping Agency (WADA). Currently, there is no implemented detection method for
12 ABT. Transfusion of one's own, long-term cryopreserved red blood cells (cryo-RBC) immediately
13 increases circulating RBC count, hemoglobin mass, blood volume and oxygen carrying capacity,
14 resulting in enhanced physical performance. Functional viability of cryo-RBC are maintained for
15 decades, but storage lesions lead to removal of damaged RBC from circulation days after transfusion,
16 with remaining circulating cryo-RBC displaying normal half-life. **Methods:** The cytosolic RBC
17 peptidome from 22 human subjects (12 men and 10 women) was analyzed by UHPLC-MS/MS before
18 and after ABT with cryo-RBC. As a control group and for investigation of confounders, 14 elite
19 athletes and 5 recreational subjects were sampled multiple times, also at high altitude. **Results:** Here
20 we report alteration in the cytosolic peptidome of circulating RBC weeks after ABT, discriminating
21 doped from non-doped human subjects. A valid discriminating multivariate model (OPLS-DA) based
22 on <200 peptides was accomplished ($R^2/Q^2 = 0.88/0.59$, P CV-ANOVA < 0.0001, ROC AUC = 0.97).
23 Models did not show bias for sex, high altitude or elite endurance training and racing. **Conclusion:**
24 Identified peptides with low intra- and inter-individual variation, and high multivariate model weight
25 and probability scores, create a direct method for the detection of autologous blood doping.

26 Key words: endurance, performance, doping, proteomics

27 **Correspondence to:** Christer Malm christer.malm@umu.se

28 Word count: 3286

29 INTRODUCTION

30 Autologous blood transfusion (ABT) enhances the athlete's performance,¹ and is viewed as doping,
31 thus banned by the World Anti-Doping Agency (WADA); but with no implemented direct detection
32 method,² it remains difficult to survey by sporting authorities. Because cold-stored (+1° to +4°C) blood
33 is viable for a maximum of 42 days,³ during which time the athlete's physical performance is
34 compromised from blood donation,^{4,5} and erythropoietin is readily detected,⁶ the blood doping method
35 of choice for cheating athletes is transfusion of one's own, long-term cryopreserved red blood cells
36 (cryo-RBC). Upon transfusion, increases are immediately observed in circulating RBC count,
37 hemoglobin mass,⁷ blood volume and oxygen carrying capacity,⁸ resulting in enhanced physical
38 performance.^{1, 9, 10} Cryo-RBC in storage maintain their function for more than a decade,^{11, 12} but
39 display storage lesions altering physical properties^{13, 14} of both cytosolic¹⁵ and membrane¹⁶ proteins,
40 leading to an expedited removal of damaged cryo-RBC from circulation 6 h to 48 h after transfusion.^{17,}
41 ¹⁸ The remaining circulating cryo-RBC display normal half-life¹⁹ despite observable altered metabolic
42 profiles²⁰ and irreversible cytosolic protein alterations, derived from the process of freezing and
43 thawing.²¹

44 Today, indirect detection of ABT exist using the hematological module of the Athletes Biological
45 Passport (ABP). The ABP uses longitudinal monitoring of standard hematological parameters to
46 identify possible blood manipulations,²² and can be considered less effective than anticipated in
47 detecting ABT.^{23, 24} Also, the ABP is affected by exercise²⁵ as well as increased fluid intake.²⁶
48 Moreover, several tests claim to detect ABT via: immunological reactions,²⁷ hematological variables,²⁸
49 phthalate/metabolites²⁹ and CO rebreathing^{30, 31}, but no test is implemented for doping detection.

50 A direct and valid detection method for ABT remains elusive and unavailable,^{1, 32, 33} but must include
51 intracellular biomarkers, as all cell-surface alterations, including storage-induced,³⁴ initiate rapid
52 removal of cryo-RBC from circulation by spleen macrophages,¹⁸ thus circumventing the effectiveness
53 of such markers for detection of ABT.

54 Proteomic and bioinformatic methodologies allows detection of sample differences in minutiae across
55 subjects and chronology. We proposed that screening the cytosolic fraction of circulating RBC
56 (RBCc) sampled before and after cryo-RBC transfusion, will provide markers specific to ABT.
57 Subsequently, applying liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis will
58 generate biomarkers (proteins and/or peptides), differentiating the two states of pre- and post-
59 transfusion, defining Clean and Doped samples, respectively. In addition, identified biomarkers will be
60 curated to remove those markers biased for sex, exercise, hypoxia and high-altitude exposure.

61 METHOD (APPENDIX 10)

62 SUBJECTS

63 Autologous blood transfusion of eight men (age 29; 24-36 years [mean; min-max]) and seven women
64 (age 27; 23-38 years) with peak oxygen consumption (VO_{2peak}); Men (4.3; 3.2-5.0 L·min⁻¹/53; 33-59
65 mL·min⁻¹·kg⁻¹) and women (3.0; 2.4-3.6 L·min⁻¹/48; 45-56 mL·min⁻¹·kg⁻¹) with five recreational
66 Control subjects sampled in parallel (Appendix 2, 3 & 9). Fourteen international level elite endurance
67 athletes investigated confounders by resting blood samples at: Sea Level (<80 m), High Altitude
68 Training (>1500 m), Hypoxic Tents (>10 h/day, 14 days, 3-4000 m) and in the Hypoxia group up to
69 28 days after a multisport race (700 km in 4.5 days reaching altitudes up to 4500 m, Appendix 2, 3 &
70 9).

71 TRANSFUSION

72 Women donated one (450 mL) and men two (900 mL) units of whole blood as s described in detail
73 previously^{1,18}. Whole blood was collected and glycerolized RBC stored at -80°C until transfusion.

74 SAMPLING

75 In total, participants (21 men and 15 women, Appendix 2, 3 & 9) gave 307 venous blood samples,
76 where 85 were in a Doped state after cryo-RBC transfusion, 173 in a Clean state and 49 samples taken
77 directly from the Blood Donation Bag (timeline for Transfusion indicated in Figure 1). Some samples
78 were used multiple times (noted as Batch I, II and III in Tables and Appendices), resulting in 392 LC-
79 MS/MS sample injections (Appendix 2, 3 & 9).

80 PREPARATION

81 Erythrocytes were lysed, the cytosol isolated and hemoglobin removed before determination of protein
82 concentration. Pre-digest internal peptide standard was added before trypsin digestion. Clean-up of
83 trypsin digest samples was performed by C18 and dried samples were stored at -80°C.

84 NANO-UPLC-MS/MS ANALYSIS

85 Internal retention time standards, pre-LC internal standard and TFA were added before injection using
86 a nanoACQUITY UltraPerformance UPLC™ (Waters). Separated peptides were analyzed using a
87 Synapt G2™ or G2Si™ (Waters). Initial data evaluation used the MassLynx™ software (Waters).

88 DATA PROCESSING AND ANALYSIS

89 Raw data processing, alignment, peptide identification, quantification (relative abundance) and
90 comparative analysis were performed using Progenesis QI for Proteomics (Waters), Protein Lynx
91 Global Server (Waters) and the open-source Skyline (<https://skyline.ms>). For peptide identification a
92 curated human proteome database (Swiss-Prot) was used, acquired from Uniprot (www.uniprot.org).

93 STATISTICS

94 Mixed Model using Restricted Maximum Likelihood (REML) and multivariate analysis (MVA),¹ with
95 Principal Component Analysis (PCA), Orthogonal Projections of Latent Structures (OPLS)³⁵, and its

96 discriminant analysis OPLS-DA³⁶ were applied. Samples from blood donation (Clean) and after
97 transfusion (Doped), High Altitude Training, Hypoxic Tents and Elite Endurance Athletes created
98 MVA models (Appendix 5 & 9). Regression (R^2) and prediction (Q^2) were investigated, with valid R^2
99 and Q^2 set to > 0.60 ,^{35,37,38} in three datasets: Training (Men), Testing (Women) and Validation (Men
100 and Women) for Screening, Selection and Validation of Biomarkers (Appendix 5 & 9).

101 CONFOUNDERS

102 Data from two LC-MS/MS analyses which differed to the biomarker screening dataset (Appendix 6),
103 were used to create four OPLS-DA models investigating confounders. Appendix 7: 1) If peptides
104 separating fresh and cryo-stored RBCc could separate Clean from Doped subject 2) Bias for Elite
105 Endurance training and 3) Summary model (four Y -variables) of Clean, Doped, Elite Athletes and
106 High-Altitude Training. Appendix 8: Bias for High Altitude Training and Hypoxic Tents.

107 PATIENT AND PUBLIC INVOLVEMENT STATEMENT

108 Participants in the study were recruited locally. Each participant was given continuous feedback.
109 Lectures informed staff, participants and colleagues of the study objectives.

110 ETHICAL CONSIDERATIONS

111 The Ethics Board for Northern Sweden approved the study (DNr: Ö1-2009, 08-196M, 2011-408-
112 32M), and transfusions performed in a hospital clinical. Risks reviewed in Appendix 1. The study was
113 conducted in accordance with the WMA Declaration of Helsinki 2013. Data is encrypted and stored on
114 security protected servers.

115 RESULTS (EXTENSIVE MODELS IN APPENDIX 5 & 9).

116 Normal distribution of samples is visualized in a PCA model for Hematological (Figure 1A) and
117 Proteomic (Figure 1B) data.

118 HEMATOLOGY

119 Autologous blood transfusion changed hematological variables (Figure 1, Table 3, Appendix 3 and 4),
120 but with large individual variations, making regression analysis and prediction of samples to Clean
121 (Before blood donation) or Doped (after transfusion of cryo-RBC) unreliable (Figure 2 and 3,
122 Appendix 3 and 4). The visualized OPLS-DA analysis (Figure 3) indicate models with low R^2 (<0.6)
123 and Q^2 (<0.2) in the Summary of Fit plot, and sensitivity and specificity displayed in the ROC curve,
124 where AUC for Men = 0.97 and Women = 0.79. Selection for prediction by VIP Pred indicate
125 different variables of importance for men and women.

126 **Interpretation:** Hematological data can generate weak regression models with low predictive power,
127 even when used in combinations.

128

FIGURE 1 HERE - Hematology

129

130

FIGURE 2 HERE – PCA models

131 **PROTEOMICS**

132 Multivariate data analysis (MVA) of quantified and identified peptides from circulating RBC cytosol
133 created significant and cross-validated PCA and OPLS-DA models for regression and prediction of
134 analyzed samples to Clean and Doped groups (Figures 3, Appendix 6). Separation of Clean and Doped
135 samples by OPLS-DA analysis resulted in R^2 and $Q^2 > 0.9$ for men, and $R^2 > 0.6$ and $Q^2 < 0.2$ for women,
136 displayed in the Summary of Fit plot. Sensitivity and specificity are displayed in the ROC curve,
137 where AUC for Men = 1.00 and Women = 0.68. Selection for prediction by VIP Pred indicate
138 different variables of importance for men and women.

139 Further results when screening for biomarkers are displayed in Figure 4, where data is divided into
140 three sets; Training (Men), Testing (Women) and Validation (Men and Women). Because the RBC
141 cytosolic fraction (Hb removed) of RBC (RBCc) had different peptidomic profile in men and women,
142 $R^2(\text{cum}) = 0.99/Q^2 = 0.92$; $P < 0.0001$, different biomarkers in each sex may be assumed. Models
143 excluding sex-separating peptides were also investigated (Appendix 6).

144 **Training (Men)** the model pared down data to the 200 most important peptides, separating Clean
145 from Doped both in PCA and OPLS-DA analysis, with high R^2/Q^2 of 0.90/0.79, cross-validated by
146 100 permutations and predicting 28/28 samples to the correct class. AUC = 0.96.

147 **Testing (Women)** of the model as accomplished by applying the 200 peptides from the Training
148 model on a cohort of women, resulted in R^2/Q^2 of 1.00/0.52, cross-validated by 100 permutations and
149 predicting 28/28 samples to the correct class. AUC = 0.92.

150 **Validation (Men and Women)** of selected peptides for prediction of Doping used both male and
151 female subjects in combination, starting with the 200 peptides from men and removing peptides until
152 an optimized model was achieved, containing 50 peptides, reaching, R^2/Q^2 of 0.88/0.59, cross-
153 validated by 100 permutations and predicting 56/56 samples to the correct class. AUC = 0.97.

154 Ranking peptides by OPLS-DA loading scores suggests potential candidates for development of
155 diagnostic tools applicable for the detection of autologous blood doping in humans (Figure 5).
156 Merging hematological and peptidomic signature variables, demonstrate a lower loading impact of
157 hematological variables, compared to peptides (Figure 5) in MVA modeling, supporting the previously
158 demonstrated¹ lack of predictive power using hematology (Figure 1, 2 and 3).

159

FIGURE 3 HERE – OPLS-DA models

160

161 FIGURE 4 HERE – Training/Testing/Validation

162

163 FIGURE 5 HERE – Loading plot

164 **CONFOUNDERS**

165 *In vitro* peptides quantified and identified from analysis of the cytosolic fraction of RBCs, harvested
166 from transfusion bags before and after cryo-preservation, created significant and cross-validated
167 OPLS-DA models for the two conditions (Bags, Figure 6). *In vitro* identified peptides did not create
168 significant and cross-validated OPLS-DA models for venous blood samples taken before and after
169 cryo-RBC transfusion (i.e. autologous blood doping, Blood Sample, Figure 6). *In vivo* peptides
170 quantified and identified from analysis of RBCc taken by venous blood sampling in humans before
171 and after cryo-RBC transfusion, created significant and cross-validated OPLS-DA models (Appendix
172 9/Table 6/Model 19). *In vivo* Doped peptides (top 200 from the OPLS-DA coefficients for Doped) also
173 separated venous blood samples taken from individuals (Elite Athletes) trained at High Altitude, living
174 in Hypoxic Tents and Elite Athlete sampled at sea level (Figure 6, Appendix 9/Table 6). In the
175 Summary plot (Figure 6), samples from Doped do not overlap with other investigated cohorts.

176 FIGURE 6 HERE – Confounders

177 **Interpretation:** Proteomic data can generate strong regression models with high predictive power,
178 both for Men and Women, with no impact (bias) from investigated confounders.

179 **DISCUSSION**

180 Autologous blood doping with cryo-RBC is detected in human subjects by unlabeled, quantitative
181 nano-UPLC-MS/MS. Comparing peptide patterns from RBCc separated Clean from Doped
182 individuals using the multivariate discriminating method OPLS-DA ($R^2 > 0.90$, $Q^2 > 0.90$, $p < 0.001$,
183 $X < 200$). Cross-validated models did not show bias for sex, strenuous physical exercise, hypoxia
184 exposure and high-altitude training in elite athletes. In comparison, hematological variables alone
185 failed to generate significant OPLS-DA models when analyzed in parallel blood samples.
186 Investigations were executed using prospective case-control, cohort and cross-sectional study designs.

187 **BIOMARKERS IN BIOLOGICAL MATRIXES**

188 Biomarkers for any diagnostics must be reliable, sensitive, specific, and discriminative.^{39, 40} In
189 addition, validation must determine predictability of unknown samples to correct state (i.e. Clean or
190 Doped). For practical implementation in anti-doping efforts to keep sports clean, aspects such as

191 available sample matrices, Doping Control Laboratory (DCL) facilities, transport systems and cost are
192 also important considerations.

193 Red blood cells are closed systems, unable to synthesis protein and with a life cycle of approximately
194 120 days in adult humans.⁴¹ Once set in circulation, RBC undergo an ageing processes, with changing
195 plasma membrane and external structures,^{3,41} making them susceptible to recognition and subsequent
196 systemic removal by spleen macropahges.^{18, 42} While homologous blood transfusion can be detected
197 via surface antigens,³ the only current method to detect autologous blood transfusion is via Hb mass by
198 CO-rebreathing.^{43, 44} The WADA research initiative states that there is no unequivocal detection
199 method for autologous blood doping, as CO is toxic it has no relevance in anti-doping control of
200 healthy athletes who would be reluctant to have a toxic agent imposed on them repeatedly. Autologous
201 blood doping with cryo-RBC is the preferred choice of cheating athletes, as RBC in cold storage
202 (+4°C) has a known clinical safety limit of 42 days after donation, necessitating repeated blood
203 donation, and subsequent decreased performance,⁴⁵ during the preparation phase for competition as the
204 red blood cell population are regenerated to compensate for the loss. Cryo-RBC on the other hand,
205 may be stored for decades.¹²

206 Regardless of storage procedure, a fraction of all transfused RBCs is damaged and, just as aging RBC,
207 removed from circulation not in 120 days but within 6 h to 48 h.¹⁹ Consequently, RBC with intact cell
208 surface proteins, and remaining in circulation 48 h after transfusion, may be viewed as circulating
209 time-stamps, containing bioinformation useful in the detection of ABT.^{46, 47} The cryo-induced
210 formation of ice crystals, permanently damaging cytosolic RBC proteins,²¹ serves as a probable, but
211 not the only inducer of potential biomarkers – creating unique detectable peptide fragments after
212 protein trypsinization. An additional advantage of using altered cytosolic biomarkers, compared to
213 hematological variables, is that plasma volume changes will not influence analytical results.

214 The present series of studies follows a general procedure for biomarker discovery and validation,^{39, 40}
215 including establishing robust baseline values by repeated sample collection at rest in all investigated
216 groups, transports and storage conditions and routine procedures in accredited, clinical laboratories.
217 Current approaches with multiplexing orthogonal biomarkers into one assay increase robustness to
218 confounders and inter-laboratory variations, while reducing analytical costs. The results are reliable,
219 validated for several known possible confounders, have high specificity, sensitivity and discriminating
220 power.³⁹

221 *TRUE POSITIVES AND NEGATIVES*

222 One unavoidable challenge when investigating ABT is the inclusion of true positives, vital for all
223 statistical analysis and legal actions. As previously directly shown by us¹, argued by others²³ and here
224 again demonstrated (Figures 2 and 3) - hematological markers are indirect indicators of ABT, and will
225 always be subject for interpretation (what are limits for normal intra-individual variation?) and

226 significant confounder (exercise, hydration, high altitude, diet, illness etc.) opening for cheating
227 athletes to be legally dismissed from conviction. When investigating hematological intra- and inter-
228 individual variations over time in Clean vs. Doped subjects, neither regression nor prediction models
229 are reliable (Appendix 5). In the context of doping detection, median/range values from elite athletes^{22,}
230 ^{31, 48} (unknown status of doping) are not relevant for individual judgements, as mean/median values
231 from true positively doped subjects¹ can also stay within 95% CI (Figure 2 & Appendix 5). Also, when
232 using cold stored RBC, detection of ABT by hematological measurements has shown low specificity
233 and sensitivity^{31, 49, 50}. Hematological variables changed with investigated confounders, even when
234 more advanced statistical approaches are applied (Figure 1).

235 The present use of clean elite athletes for comparison is not often possible when validating biomarkers
236 for doping, as athletes cannot serve as subjects. Using cohorts of elite athletes from routine sampling
237 as controls adds uncertainty to any model, as their true state of Clean or Doped cannot be known. Elite
238 athletes participating in this study volunteered to live for extended periods of time in hypoxic tents,
239 before training and competing at high altitude. Knowing they would be tested for blood doping, it is
240 highly unlikely doped athletes are included, also confirmed by the OPLS-DA analysis.

241 *WINDOW OF DETECTION*

242 Theoretically, transfusion of cryo-RBC can be detected for up to 120 days, if the youngest RBCs at
243 time of donation could be identified after transfusion.¹⁹ Limits of Quantification (LOQ) with the
244 presented method is still not fully investigated, but a few samples (N=14) taken four and five weeks
245 after transfusion (Batch I) are below critical limits (99%) when analyzed by Hotelling's T^2 indicating
246 that these samples are no different compared to samples taken one to three weeks after transfusion.
247 Because cryo-induced peptide abundance diminish as RBCs are aged and removed, LOQ should be
248 determined by target analysis methods. Determining LOQ will also be valuable for detection of micro-
249 dosing with cryo-RBC, a practice likely to be used by cheating athletes to avoid detection.

250 *ALTERNATIVE INTERPRETATIONS AND LIMITATIONS*

251 An alternative biomarker selection procedure for Clean vs. Doped models could be to exclude the
252 most important (highest OPLS-DA coefficient scores) peptides separating RBCc from Men and
253 Women taken at rest (Clean). This approach may potentially remove peptides important for detecting
254 reinfusion of only one unit cryo-RBC. Creating OPLS-DA models that include 5000 peptides which
255 are most relevant for separating of Men and Women, then selecting the 200 peptides with the highest
256 coefficient score for Doped, creates models for Clean vs. Doped, still biased for sex in the regression
257 models, but without predictive power: Men vs. Women $R^2 = 0.45$ and $Q^2 = -1.55$, CV-ANOVA p
258 $=1.00$. Data remaining after removing 5 000 peptides from the model of Men vs. Women, provides an
259 OPLS-DA model for Clean vs. Doped using 200 peptides with $R^2/Q^2 = 0.64/0.24$, CV-ANOVA $p <$
260 0.001 . Removing 10 000 peptides gives $R^2/Q^2 = 0.79/0.38$, CV-ANOVA $p < 0.001$. As discussed,

261 approaching the biomarker selection via a Training set consisting of Men (reinfused with two units
262 RBC) resulted in stronger regression and prediction models (Figure 4). Alternatively, the models for
263 sex investigate cryo-RBC reinfusion of one vs. two units. Data from the present study design cannot
264 distinguish these two options.

265 Regardless, with the presented list of peptides (Appendix 6 & 9) ABT can be detected in both men and
266 women, reinfused with either one or two units cryo-RBC for at least two weeks after reinfusion.

267 CONCLUSION

- 268 • Doping with ABT is directly detected by cryo-induced alterations in cytosolic RBC peptides,
269 with high sensitivity and specificity in both men and women.
- 270 • Elite endurance training at low and high altitude did not significantly affect peptides
271 discriminating Clean from Doped samples.
- 272 • Presented peptides can be used for direct detection of autologous blood doping using standard
273 equipment available in Doping Control Laboratories.

274 FUTURE RESEARCH

275 The potential of selected peptides for labeling and direct detection of autologous blood doping by
276 target analysis should be explored, with independent prospective case-control trials and cross-sectional
277 studies, including inter- and intra-laboratory analytical variability. Larger, both-sex cohorts of clean
278 and doped subjects, elite athletes and different ethnic groups need to be sampled for investigation of
279 sensitivity, specificity, false positive and likelihood ratios.

280 ACKNOWLEDGEMENTS

281 Outstanding contributions were given by: The staff at Sunderby Hospital, Luleå for hosting the first
282 series of blood transfusions, under the medical responsibility of Staffan Wikström. The staff at
283 Winternet, Boden for performing all exercise testing and blood sample collection, especially Anna
284 Tano-Nordin and Eva Edholm. The staff at Björknäs Health Center, Boden under guidance of Lillian
285 Falk for organizing the first round of blood donations. The staff at Huddinge Blood Central, where
286 Eva Trollin and Linda Larsson were responsible for blood cryopreservation, and head of unit Hans
287 Gulliksson kindly supported the project. Blood donation, cryopreservation and transfusion, as well as
288 blood sampling, has also been executed by the Center for Stem Cell Apheresis and Management at
289 Huddinge University Hospital, where Emma Watz, Beatrice Asperval Diedrich and Peter Matha
290 managed the study. Ogonna Obudulu for consultation on multivariate statistics. Gunnar Wingsle for
291 technical support with LC-MS/MS, Raik Wagner and Johan Jakobsson for proof-reading and
292 improving the manuscript. All participating subjects for enduring blood loss, exhaustive exercise and
293 numerous trips to the labs.

294 **CONTRIBUTORS**

295 CM conceived the idea, received funding, developed the methodology and clinical study, performed
296 statistical analysis and was lead writer. IG, MH, PL developed the methodology, prepared samples,
297 executed LC-MS/MS analysis and data cleanup. JL, LG, CH developed the method and executed LC-
298 MS/MS analysis. NK developed the methodology, designed experiments and improved data cleanup.
299 All author participated in writing and editing the final manuscript.

300 **FUNDING**

301 This work was funded by WADA: R07A1CM, 08C06CM and T13M04CM, VINNOVA; 2009-00462,
302 2013-05410, 2015-05299, 2018-0188, Centrum för Idrottsforskning; 2008 88/08 and Umeå Biotech
303 Incubator. The funders had no role in study design, data collection and analysis, decision to publish, or
304 preparation of the manuscript.

305 **REFERENCES**



- 306 1. Malm CB, Khoo NS, Granlund I, et al. Autologous Doping with Cryopreserved Red Blood Cells -
307 Effects on Physical Performance and Detection by Multivariate Statistics. *PLoS One*
308 2016;11(6):e0156157. doi: 10.1371/journal.pone.0156157
- 309 2. WADA. Blood doping. <https://www.wada-ama.org/en/questions-answers/blood-doping#item-596>,
310 2019.
- 311 3. Almizraq R, Tchir JD, Holovati JL, et al. Storage of red blood cells affects membrane composition,
312 microvesiculation, and in vitro quality. *Transfusion (Paris)* 2013;53(10):2258-67. doi:
313 10.1111/trf.12080 [published Online First: 2013/01/17]
- 314 4. Berglund B, Birgegard G, Wide L, et al. Effects of blood transfusions on some hematological
315 variables in endurance athletes. *Med Sci Sports Exerc* 1989;21(6):637-42. [published Online First:
316 1989/12/01]
- 317 5. Ekblom B, Goldbarg AN, Gullbring B. Response to exercise after blood loss and reinfusion. *J Appl*
318 *Physiol* 1972;33(2):175-80.
- 319 6. Lasne F, Martin L, Crepin N, et al. Detection of isoelectric profiles of erythropoietin in urine:
320 differentiation of natural and administered recombinant hormones. *Anal Biochem* 2002;311(2):119-26.
321 doi: S0003269702004074 [pii] [published Online First: 2002/12/10]
- 322 7. Ashenden M, Morkeberg J. Net haemoglobin increase from reinfusion of refrigerated vs. frozen red
323 blood cells after autologous blood transfusions. *Vox Sang* 2011;101(4):320-6. doi: 10.1111/j.1423-
324 0410.2011.01493.x [published Online First: 2011/05/04]

- 325 8. Boning D, Maassen N, Pries A. The Hematocrit Paradox - How Does Blood Doping Really Work?
326 *Int J Sports Med* 2011;32(4):242-46. doi: 10.1055/s-0030-1255063
- 327 9. Schmidt W, Prommer N. Impact of alterations in total hemoglobin mass on VO₂max. *Exerc Sport*
328 *Sci Rev* 2010;38(2):68-75. doi: 10.1097/JES.0b013e3181d4957a [published Online First: 2010/03/26]
- 329 10. Lundby C, Montero D, Joyner M. Biology of VO₂ max: looking under the physiology lamp. *Acta*
330 *Physiol (Oxf)* 2017;220(2):218-28. doi: 10.1111/apha.12827 [published Online First: 2016/11/27]
- 331 11. Valeri CR, Ragno G, Pivacek LE, et al. An experiment with glycerol-frozen red blood cells stored
332 at -80 degrees C for up to 37 years. *Vox Sang* 2000;79(3):168-74. doi: 10.1159/000031236 [published
333 Online First: 2000/12/09]
- 334 12. MacLare G. Request for the extended storage of frozen red cells beyond 10 years to be considered
335 for inclusion within UK Guidelines. 2016
- 336 13. Bizjak DA, Jungen P, Bloch W, et al. Cryopreservation of red blood cells: Effect on rheologic
337 properties and associated metabolic and nitric oxide related parameters. *Cryobiology* 2018;84:59-68.
338 doi: 10.1016/j.cryobiol.2018.08.001 [published Online First: 2018/08/07]
- 339 14. Pallotta V, D'Amici GM, D'Alessandro A, et al. Red blood cell processing for cryopreservation:
340 from fresh blood to deglycerolization. *Blood Cells Mol Dis* 2012;48(4):226-32. doi:
341 10.1016/j.bcmd.2012.02.004 [published Online First: 2012/03/20]
- 342 15. Walpurgis K, Kohler M, Thomas A, et al. Storage-induced changes of the cytosolic red blood cell
343 proteome analyzed by 2D DIGE and high-resolution/high-accuracy MS. *Proteomics*
344 2012;12(21):3263-72. doi: 10.1002/pmic.201200280
- 345 16. Holovati JL, Wong KA, Webster JM, et al. The effects of cryopreservation on red blood cell
346 microvesiculation, phosphatidylserine externalization, and CD47 expression. *Transfusion (Paris)*
347 2008;48(8):1658-68. doi: 10.1111/j.1537-2995.2008.01735.x [published Online First: 2008/05/17]
- 348 17. Hult A, Malm C, Oldenborg PA. Transfusion of cryopreserved human red blood cells into healthy
349 humans is associated with rapid extravascular hemolysis without a proinflammatory cytokine
350 response. *Transfusion (Paris)* 2013;53(1):28-33. doi: 10.1111/j.1537-2995.2012.03710.x
- 351 18. Hult A, Fredrik T, Christer M, et al. Phagocytosis of liquid-stored red blood cells in vitro requires
352 serum and macrophage scavenger receptors. *Submitted* 2015
- 353 19. Mock DM, Matthews NI, Zhu S, et al. Red blood cell (RBC) survival determined in humans using
354 RBCs labeled at multiple biotin densities. *Transfusion (Paris)* 2011;51(5):1047-57. doi:
355 10.1111/j.1537-2995.2010.02926.x


- 356 20. D'Alessandro A, Gray AD, Szczepiorkowski ZM, et al. Red blood cell metabolic responses to
357 refrigerated storage, rejuvenation, and frozen storage. *Transfusion (Paris)* 2017;57(4):1019-30. doi:
358 10.1111/trf.14034 [published Online First: 2017/03/16]
- 359 21. Poisson JS, Acker JP, Briard JG, et al. Modulating Intracellular Ice Growth with Cell-Permeating
360 Small-Molecule Ice Recrystallization Inhibitors. *Langmuir* 2019;35(23):7452-58. doi:
361 10.1021/acs.langmuir.8b02126 [published Online First: 2018/08/19]
- 362 22. Berglund B, Ekblom B, Ekblom E, et al. The Swedish Blood Pass project. *Scand J Med Sci Sports*
363 2007;17(3):292-7.
- 364 23. Pialoux V, Mounier R, Brugniaux JV. Hemoglobin and hematocrit are not such good candidates to
365 detect autologous blood doping. *Int J Hematol* 2009;89(5):714-5. doi: 10.1007/s12185-009-0330-5
366 [published Online First: 2009/05/21]
- 367 24. Thevis M, Kohler M, Schanzer W. New drugs and methods of doping and manipulation. *Drug*
368 *discovery today* 2008;13(1-2):59-66. doi: S1359-6446(07)00492-8 [pii]
369 10.1016/j.drudis.2007.11.003 [published Online First: 2008/01/15]
- 370 25. Morkeberg JS, Belhage B, Damsgaard R. Changes in blood values in elite cyclist. *Int J Sports Med*
371 2009;30(2):130-8. doi: 10.1055/s-2008-1038842 [published Online First: 2008/09/06]
- 372 26. Bejder J, Hoffmann MF, Ashenden M, et al. Acute hyperhydration reduces athlete biological
373 passport OFF-hr score. *Scand J Med Sci Sports* 2015 doi: 10.1111/sms.12438
- 374 27. Pottgiesser T, Schumacher YO, Funke H, et al. Gene expression in the detection of autologous
375 blood transfusion in sports--a pilot study. *Vox Sang* 2009;96(4):333-6. doi: VOX1169 [pii]
376 10.1111/j.1423-0410.2009.01169.x [published Online First: 2009/03/04]
- 377 28. Gore CJ, Parisotto R, Ashenden MJ, et al. Second-generation blood tests to detect erythropoietin
378 abuse by athletes. *Haematologica* 2003;88(3):333-44. [published Online First: 2003/03/26]
- 379 29. Monfort N, Ventura R, Latorre A, et al. Urinary di-(2-ethylhexyl)phthalate metabolites in athletes
380 as screening measure for illicit blood doping: a comparison study with patients receiving blood
381 transfusion. *Transfusion (Paris)* 2009;50(1):145-9. doi: TRF2352 [pii]
382 10.1111/j.1537-2995.2009.02352.x [published Online First: 2009/08/22]
- 383 30. Pottgiesser T, Umhau M, Ahlgrim C, et al. Hb mass measurement suitable to screen for illicit
384 autologous blood transfusions. *Med Sci Sports Exerc* 2007;39(10):1748-56. doi:
385 10.1249/mss.0b013e318123e8a6

- 386 00005768-200710000-00011 [pii] [published Online First: 2007/10/03]
- 387 31. Morkeberg J, Sharpe K, Belhage B, et al. Detecting autologous blood transfusions: a comparison
388 of three passport approaches and four blood markers. *Scand J Med Sci Sports* 2011;21(2):235-43. doi:
389 10.1111/j.1600-0838.2009.01033.x [published Online First: 2009/11/12]
- 390 32. Thevis M, Kuuranne T, Walpurgis K, et al. Annual banned-substance review: analytical
391 approaches in human sports drug testing. *Drug Test Anal* 2016;8(1):7-29. doi: 10.1002/dta.1928
- 392 33. Fitch KD. Blood doping at the Olympic Games. *J Sport Med Phys Fit* 2017;57(11):1526-32. doi:
393 10.23736/S0022-4707.17.06948-1
- 394 34. Al-Thani AM, Voss SC, Al-Menhali AS, et al. Whole Blood Storage in CPDA1 Blood Bags Alters
395 Erythrocyte Membrane Proteome. *Oxid Med Cell Longev* 2018;2018:6375379. doi:
396 10.1155/2018/6375379 [published Online First: 2018/12/12]
- 397 35. Bylesjo M, Eriksson D, Sjodin A, et al. Orthogonal projections to latent structures as a strategy for
398 microarray data normalization. *BMC Bioinformatics* 2007;8:207. doi: 1471-2105-8-207 [pii]
399 10.1186/1471-2105-8-207 [published Online First: 2007/06/20]
- 400 36. Pohjanen E, Thysell E, Jonsson P, et al. A multivariate screening strategy for investigating
401 metabolic effects of strenuous physical exercise in human serum. *J Proteome Res* 2007;6(6):2113-20.
402 doi: 10.1021/pr070007g [published Online First: 2007/04/13]
- 403 37. Wold S, Esbensen K, Geladi P. Principal Component Analysis. *Chemometrics and Intelligent*
404 *Laboratory Systems* 1987;2:37-52.
- 405 38. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. *J Proteome Res* 2007;6(2):469-
406 79. doi: 10.1021/pr060594q [published Online First: 2007/02/03]
- 407 39. Aikin R, Baume N, Equey T, et al. Biomarkers of doping: uses, discovery and validation.
408 *Bioanalysis* 2020 doi: 10.4155/bio-2020-0035 [published Online First: 2020/06/02]
- 409 40. Brun V, Couté Y, editors. *Proteomics for Biomarker Discovery: Methods and Protocols*.
410 Université Grenoble Alpes, CEA, Inserm, BGE U1038GrenobleFrance: Human Press, 2019.
- 411 41. Bosman GJ. Survival of red blood cells after transfusion: processes and consequences. *Front*
412 *Physiol* 2013;4:376. doi: 10.3389/fphys.2013.00376
- 413 42. Hult A. Towards a detailed understanding of the red blood cell storage lesion: and its
414 consequences for in vivo survival following transfusion. Umeå Universiy, 2015.


- 415 43. Schmidt W, Prommer N. The optimised CO-rebreathing method: a new tool to determine total
416 haemoglobin mass routinely. *Eur J Appl Physiol* 2005;95(5-6):486-95. doi: 10.1007/s00421-005-
417 0050-3 [published Online First: 2005/10/14]
- 418 44. Siebenmann C, Keiser S, Robach P, et al. CORP: The assessment of total hemoglobin mass by
419 carbon monoxide rebreathing. *J Appl Physiol* 2017;123(3):645-54. doi:
420 10.1152/jappphysiol.00185.2017 [published Online First: 2017/07/01]
- 421 45. Celsing F, Nystrom J, Pihlstedt P, et al. Effect of long-term anemia and retransfusion on central
422 circulation during exercise. *J Appl Physiol (1985)* 1986;61(4):1358-62.
- 423 46. Karsten E, Breen E, Herbert BR. Red blood cells are dynamic reservoirs of cytokines. *Sci Rep*
424 2018;8(1):3101. doi: 10.1038/s41598-018-21387-w
- 425 47. Carvalho AS, Rodriguez MS, Matthiesen R. Red Blood Cells in Clinical Proteomics. *Methods Mol*
426 *Biol* 2017;1619:173-81. doi: 10.1007/978-1-4939-7057-5_13
- 427 48. Malcovati L, Pascutto C, Cazzola M. Hematologic passport for athletes competing in endurance
428 sports: a feasibility study. *Haematologica* 2003;88(5):570-81.
- 429 49. Pottgiesser T, Echteler T, Sottas PE, et al. Hemoglobin mass and biological passport for the
430 detection of autologous blood doping. *Med Sci Sports Exerc* 2012;44(5):835-43. doi:
431 10.1249/MSS.0b013e31823bcfb6
- 432 50. Sallet P, Brunet-Guedj E, Mornex R, et al. Study of a new indirect method based on absolute
433 norms of variation to detect autologous blood transfusion. *Int J Hematol* 2008;88(4):362-8. doi:
434 10.1007/s12185-008-0182-4 [published Online First: 2008/10/24]
- 435





Erythrocytes (cells $10^{12} \cdot L^{-1}$)



Hemoglobin (g·L⁻¹)



medRxiv preprint doi: <https://doi.org/10.1101/2020.07.04.20146217>; this version posted July 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.







Hematology





OPLS-DA

ROC

Biomarker Selection



Peptidomics



medRxiv preprint doi: <https://doi.org/10.1101/2020.07.04.20146217>; this version posted July 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.






PCA

OPLS-DA






Validation

Prediction






Train




Test



Valid




Combined X-Y covariances




Preprint doi: <https://doi.org/10.1101/2020.07.04.20146217>; this version posted July 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.


Peptides from Blood Transfusion Bags for Doping Detection



No Bias for High Altitude



No Bias for Elite Endurance Training



Summary of Confounders

